Abbott receives FDA clearance for AI-powered coronary imaging platform

April 28, 2026 9:02 AM

Abbott (NYSE: ABT) received U.S. Food and Drug Administration clearance and CE Mark for its Ultreon 3.0 Software, an artificial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found